Research progress regarding programmed cell death 1/programmed cell death ligand 1 inhibitors combined with targeted therapy for treating hepatocellular carcinoma

In recent years, a number of targeted therapeutic agents have achieved success in phase III trials in patients with advanced hepatocellular carcinoma (HCC), including sorafenib, lenvatinib, and regorafenib. Immunotherapy is considered to be an effective treatment for advanced HCC. Immune checkpoint...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of gastrointestinal surgery Vol. 13; no. 10; pp. 1136 - 1148
Main Authors Zheng, Lin-Lin, Tao, Chang-Cheng, Tao, Zong-Gui, Zhang, Kai, Wu, An-Ke, Wu, Jian-Xiong, Rong, Wei-Qi
Format Journal Article
LanguageEnglish
Published Baishideng Publishing Group Inc 27.10.2021
Subjects
Minireviews
Online AccessGet full text

Cover

More Information
Summary:In recent years, a number of targeted therapeutic agents have achieved success in phase III trials in patients with advanced hepatocellular carcinoma (HCC), including sorafenib, lenvatinib, and regorafenib. Immunotherapy is considered to be an effective treatment for advanced HCC. Immune checkpoint inhibitors targeting programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) are important antitumor immunotherapy agents that represent breakthroughs in the treatment of advanced HCC. However, treating advanced HCC is still a great challenge, and the need for new treatments remains urgent. This review briefly summarizes the research progress in the use of PD-1/PD-L1 inhibitors combined with targeted therapy for treating HCC.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Supported by CAMS Innovation Fund for Medical Science (CIFMS), No. CAMS-2016-I2M-3-025; and Beijing Hope Run Special Fund of Cancer Foundation of China, No. LC2020L05.
Corresponding author: Wei-Qi Rong, MD, Associate Professor, Surgeon, Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, No. 17 Panjiayuan South Lane, Beijing 100021, China. rongweiqi@sina.com
Author contributions: Zheng LL and Tao CC wrote the manuscript, and contributed equally to this work; Tao ZG, Zhang K, and Wu AK contributed to the design, and critically reviewed and revised the manuscript; Wu JX and Rong WQ revised the draft; all authors reviewed and approved the final version.
ISSN:1948-9366
1948-9366
DOI:10.4240/wjgs.v13.i10.1136